Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Common side effects of MariTide Gastrointestinal events affected more than 90% of people taking MariTide, similar to other GLP-1 medications: Nausea (most common) Vomiting Constipation Diarrhea Abdominal discomfort Most gastrointestinal side effects reported in the MariTide trials were mild to moderate in severity, tended to occur early in treatment, and often decreased over time
Retatrutide is an investigational triple agonist that simultaneously activates GIP, GLP-1, and glucagon receptors, distinguishing it from approved agents such as semaglutide and tirzepatide
DPP4 3~5 ,
Several critical research gaps remain to be addressed
After 24 weeks of treatment, significant reductions in neuropathy symptom and disability scores and in neurophysiological parameters were seen in both groups, with no difference between the two drugs safety-wise
Our complete semaglutide vs tirzepatide comparison guide covers this in detail, but here are the key differences in weight loss outcomes: Average Weight Loss Comparison Semaglutide (STEP-1 trial, 68 weeks): Average weight loss: 14.9% 69.1% lost 10% or more 50.5% lost 15% or more Tirzepatide (SURMOUNT-1 trial, 72 weeks at 15 mg dose): Average weight loss: 22.5% 89% lost 10% or more 78% lost 15% or more Tirzepatide shows higher average weight loss in clinical trials, though both medications demonstrate significant effectiveness
